@prefix this: . @prefix sub: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "bleomycin for injection should be considered a palliative treatment it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents squamous cell carcinoma head and neck including mouth tongue tonsil nasopharynx oropharynx sinus palate lip buccal mucosa gingivae epiglottis skin larynx penis cervix and vulva the response to bleomycin is poorer in patients with previously irradiated head and neck cancer lymphomas hodgkin s disease non hodgkin s lymphoma testicular carcinoma embryonal cell choriocarcinoma and teratocarcinoma bleomycin has also been shown to be useful in the management of malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation nkg:SymptomaticReliefIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "ipESaljKUJaCl1pPlNS8kDaOZBJLJc6FGSPX4OgOMhapTjTfGWRMLCFbNMjwTLxhlvNEH92/InsAVyGb8oBU9U24Y+AWJHw2YMGxBPw2t6j19aVWHX4Zdq79GwTxTmndLO4Cfs8llXh5FnIpA3GK9D0VNDRDDOB9NbO4e627oXA="; npx:hasSignatureTarget this: . this: dct:created "2021-06-12T14:59:47.056+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }